Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Angiomax anticoagulant · 3 trials · 7 indications
: In-hospital acute procedural success, defined as the absence of death, Q wave myocardial infarction (MI), repeat coronary revascularization, and stroke (hemorrhagic or ischemic) at hospital discharge or Day 7 after surgery ('Day 7/discharge'), whichever occurs first.
| Name | Type | Description |
|---|---|---|
| Angiomax (bivalirudin) anticoagulant | DRUG | - |
Inclusion Criteria: 1. Patients \>18 years of age. 2. Symptoms of STEMI for at least 30 min within previous 12 hours AND * ST-segment elevation in at least 2 contiguous leads or new Left Branch Bundle Block (LBBB), OR existing LBBB with positive troponin * Residual high grade stenosis and as...
Angiomax is used for thrombocytopenia, unstable angina, and myocardial infarction. It is a small molecule cardiovascular drug being developed by Novartis AG. Angiomax is also studied in conditions like thrombosis, cardiac disease, and coronary artery bypass surgery.
Angiomax is a small molecule anticoagulant. It targets thrombin, a key enzyme in the blood clotting process. By inhibiting thrombin, Angiomax helps prevent blood clots in patients with cardiovascular conditions.
Angiomax is developed by Novartis AG, a multinational pharmaceutical company. Novartis is listed on the stock exchange under the ticker symbol NVS.
Angiomax is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. All three completed trials for Angiomax were Phase 3 studies.
Angiomax has completed three Phase 3 clinical trials. These include NCT00073580 for thrombocytopenia and thrombosis in coronary artery bypass surgery, NCT00093158 for unstable angina and myocardial infarction, and NCT00093184 for acute myocardial infarction undergoing primary PCI.
Angiomax is also known as bivalirudin. The clinical trial NCT00093184 specifically refers to bivalirudin in patients with acute myocardial infarction undergoing primary PCI, confirming that Angiomax and bivalirudin are the same drug.